Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) was downgraded by stock analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a report released on Tuesday.

A number of other research analysts have also weighed in on BHVN. Zacks Investment Research lowered shares of Biohaven Pharmaceutical Holding Co from a “hold” rating to a “sell” rating in a research report on Wednesday, August 16th. Piper Jaffray Companies reissued a “buy” rating and set a $54.00 price target on shares of Biohaven Pharmaceutical Holding Co in a research report on Tuesday, September 12th. Needham & Company LLC restated a “buy” rating and set a $43.00 price objective (up previously from $30.00) on shares of Biohaven Pharmaceutical Holding Co in a report on Wednesday, September 13th. Morgan Stanley raised their price objective on shares of Biohaven Pharmaceutical Holding Co from $28.00 to $47.00 and gave the stock an “overweight” rating in a report on Monday, September 25th. Finally, William Blair restated an “outperform” rating on shares of Biohaven Pharmaceutical Holding Co in a report on Tuesday, October 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $40.80.

Biohaven Pharmaceutical Holding Co (NASDAQ BHVN) opened at $25.39 on Tuesday. Biohaven Pharmaceutical Holding Co has a 12-month low of $17.00 and a 12-month high of $39.51.

TRADEMARK VIOLATION NOTICE: “Biohaven Pharmaceutical Holding Co Ltd (BHVN) Downgraded by BidaskClub” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.thecerbatgem.com/2017/11/14/biohaven-pharmaceutical-holding-co-ltd-bhvn-downgraded-by-bidaskclub.html.

In related news, CEO Vlad Coric sold 150,000 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $29.41, for a total transaction of $4,411,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Kimberly Gentile sold 5,000 shares of Biohaven Pharmaceutical Holding Co stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $29.28, for a total transaction of $146,400.00. Following the completion of the transaction, the vice president now owns 5,000 shares of the company’s stock, valued at approximately $146,400. The disclosure for this sale can be found here. Insiders have sold 185,000 shares of company stock valued at $5,435,400 in the last 90 days.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Legal & General Group Plc purchased a new position in shares of Biohaven Pharmaceutical Holding Co in the third quarter worth about $119,000. Nationwide Fund Advisors purchased a new position in shares of Biohaven Pharmaceutical Holding Co in the third quarter worth about $214,000. American International Group Inc. purchased a new position in shares of Biohaven Pharmaceutical Holding Co in the third quarter worth about $251,000. State of Wisconsin Investment Board purchased a new position in shares of Biohaven Pharmaceutical Holding Co in the third quarter worth about $262,000. Finally, Deschutes Portfolio Strategy LLC purchased a new position in shares of Biohaven Pharmaceutical Holding Co in the third quarter worth about $374,000.

About Biohaven Pharmaceutical Holding Co

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Analyst Recommendations for Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN)

Receive News & Stock Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related stocks with our FREE daily email newsletter.